Human lymphoid tumor, bladder cancer, and breast cancer preclinical models show that anti-CD47 antibody treatment promotes adaptive immunity and exerts anti-tumor effects via CD8+T cells and dendritic cells (129). Here, CD47 is linked to neoplasm.